AG
SRPT icon

Advisor Group’s Sarepta Therapeutics SRPT Stock Holding History

Advisor Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-100
Closed -$1K – 4793
2016
Q4 		$1K Buy
+100
New +$4.02K ﹤0.01% 4394

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Advisor Group's SRPT Position: Q4 2019 in Review

Advisor Group reduced its Sarepta Therapeutics (SRPT) stake by 8% in Q4 2019, selling an estimated $98.3K and leaving 11,263 shares worth $1.45M. The position accounts for 0.01% of the portfolio, ranked #982.

Advisor Group first reported a position in SRPT in Q2 2016 and has held it in 15 quarters since. The position peaked at $4.3M in Q3 2018. 389 funds tracked by Wall St. Rank hold SRPT as of Q4 2019.

  • Advisor Group held 11,263 shares of Sarepta Therapeutics worth $1.45M as of Q4 2019.
  • Advisor Group sold 974 Sarepta Therapeutics shares in Q4 2019, an estimated $98.3K.
  • Sarepta Therapeutics made up 0.01% of Advisor Group's portfolio in Q4 2019, its #982 holding.
  • Advisor Group first reported a position in Sarepta Therapeutics in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's Sarepta Therapeutics position peaked at $4.3M in Q3 2018.
  • 389 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.